American Century Companies Inc. decreased its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 99.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 744 shares of the medical research company’s stock after selling 404,837 shares during the period. American Century Companies Inc.’s holdings in Bio-Rad Laboratories were worth $479,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of BIO. First Mercantile Trust Co. bought a new position in Bio-Rad Laboratories in the first quarter valued at about $57,000. CSat Investment Advisory L.P. boosted its holdings in Bio-Rad Laboratories by 45.2% in the first quarter. CSat Investment Advisory L.P. now owns 122 shares of the medical research company’s stock valued at $70,000 after acquiring an additional 38 shares during the last quarter. Eaton Vance Management bought a new position in Bio-Rad Laboratories in the first quarter valued at about $109,000. E Fund Management Co. Ltd. bought a new position in Bio-Rad Laboratories in the first quarter valued at about $117,000. Finally, Lazard Asset Management LLC boosted its holdings in Bio-Rad Laboratories by 10.5% in the first quarter. Lazard Asset Management LLC now owns 242 shares of the medical research company’s stock valued at $138,000 after acquiring an additional 23 shares during the last quarter. Institutional investors and hedge funds own 63.14% of the company’s stock.
A number of equities analysts have issued reports on the company. Zacks Investment Research upgraded Bio-Rad Laboratories from a “hold” rating to a “strong-buy” rating and set a $806.00 target price on the stock in a report on Wednesday, August 4th. Wells Fargo & Company raised their target price on Bio-Rad Laboratories from $735.00 to $930.00 and gave the stock an “overweight” rating in a report on Friday, July 30th.
NYSE BIO opened at $782.52 on Tuesday. The firm has a market cap of $23.30 billion, a P/E ratio of 5.83 and a beta of 0.85. The stock’s 50-day moving average is $757.78 and its 200-day moving average is $658.80. Bio-Rad Laboratories, Inc. has a one year low of $490.73 and a one year high of $832.70.
Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Wednesday, July 28th. The medical research company reported $3.54 EPS for the quarter, topping the Zacks’ consensus estimate of $2.66 by $0.88. The company had revenue of $715.93 million for the quarter, compared to analyst estimates of $610.40 million. Bio-Rad Laboratories had a return on equity of 4.65% and a net margin of 140.48%. As a group, analysts anticipate that Bio-Rad Laboratories, Inc. will post 14.2 EPS for the current fiscal year.
Bio-Rad Laboratories Profile
Bio-Rad Laboratories, Inc engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments.
Featured Story: Dividend Aristocrat Index
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.